Page 841 - Read Online
P. 841

Wickremesekera et al. J Cancer Metastasis Treat 2019;5:62  I  http://dx.doi.org/10.20517/2394-4722.2019.09            Page 9 of 9

               7.   Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, et al. Brain metastases: pathobiology and emerging targeted therapies.
                   Acta Neuropathol 2012;123:205-22.
               8.   Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic
                   melanoma. N Engl J Med 2010;363:711-23.
               9.   Margolin K. The promise of molecularly targeted and immunotherapy for advanced melanoma. Curr Treat Options Oncol 2016;17:48.
               10.  Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
               11.  Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, et al. Survival in BRAF V600-mutant advanced melanoma treated with
                   vemurafenib. N Engl J Med 2012;366:707-14.
               12.  Cagney DN, Alexander BM, Hodi FS, Buchbinder EI, Ott PA, et al. Rapid progression of intracranial melanoma metastases controlled
                   with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol 2016;129:389-93.
               13.  Weidle UH, Birzele F, Kollmorgen G, Rüger R. Dissection of the process of brain metastasis reveals targets and mechanisms for
                   molecular-based intervention. Cancer Genomics Proteomics 2016;13:245-58.
               14.  Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology (Williston Park) 2014;28:1101-7.
               15.  Shipitsin M, Polyak K. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 2008;88:459-63.
               16.  Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells.
                   Proc Nat Acad Sci 2003;100:3983-8.
               17.  Bradshaw A, Wickremesekera A, Brasch HD, Chibnall AM, Davis PF, et al. Cancer stem cells in glioblastoma multiforme. Front Surg
                   2016;3:48.
               18.  Ram R, Brasch HD, Dunne JC, Davis PF, Tan ST, et al. The identification of three cancer stem cell subpopulations within moderately
                   differentiated lip squamous cell carcinoma. Front Surg 2017;4:12.
               19.  Baillie R, Itinteang T, Yu HH, Brasch HD, Davis PF, et al. Cancer stem cells in moderately differentiated oral tongue squamous cell
                   carcinoma. J Clin Pathol 2016;69:742-4.
               20.  Yu HH, Featherston T, Tan ST, Chibnall AM, et al. Characterization of cancer stem cells in moderately differentiated buccal mucosal
                   squamous cell carcinoma. Front Surg 2016;3:46.
               21.  Wickremesekera AC, Brasch HD, Lee VM, Davis PF, Woon K, et al. Putative cancer stem cell subpopulations in metastatic melanoma
                   to the brain. J Clin Neurosci 2019;60:112-6.
               22.  Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005;16:293-9.
               23.  Farag E, Sessler DI, Ebrahim Z, Kurz A, Morgan J, et al. The renin angiotensin system and the brain: New developments. J Clin
                   Neurosci 2017;46:1-8.
               24.  Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, Nguyen G, Wostl W, et al. Renin and angiotensinogen expression and
                   functions in growth and apoptosis of human glioblastoma. Br J Cancer 2004;90:1059-68.
               25.  Arundhathi A, Chuang WH, Chen JK, Wang SE, Shyr YM, et al. Prorenin receptor acts as a potential molecular target for pancreatic
                   ductal adenocarcinoma diagnosis. Oncotarget 2016;7:55437-48.
               26.  Bradshaw AR, Wickremesekera AC, Brasch HD, Chibnall AM, Davis PF, et al. Glioblastoma multiforme cancer stem cells express
                   components of the renin-angiotensin system. Front Surg 2016;3:51.
               27.  Featherston T, Yu HH, Dunne JC, Chibnall AM, Brasch HD, et al. Cancer stem cells in moderately differentiated buccal mucosal
                   squamous cell carcinoma express components of the renin-angiotensin system. Front Surg 2016;3:52.
               28.  Ram RS, Brasch HD, Dunne JC, Davis PF, Tan ST, et al. Cancer stem cells in moderately differentiated lip squamous cell carcinoma
                   express components of the renin–angiotensin system. Front Surg 2017;4:30.
               29.  Baillie R, Itinteang T, Yu HH, Brasch HD, Davis PF, et al. Cancer stem cells in moderately differentiated oral tongue squamous cell
                   carcinoma express components of the renin–angiotensin system. J Clin Pathol 2016;69:942-5.
               30.  Tan EM, Chudakova DA, Davis PF, Brasch HD, Itinteang T, et al. Characterisation of subpopulations of myeloid cells in infantile
                   haemangioma. J Clin Pathol 2015;68:571-4.
               31.  Steckelings UM, Wollschläger T, Peters J, Henz BM, Hermes B, et al. Human skin: source of and target organ for angiotensin II. Exp
                   Dermatol 2004;13:148-54.
               32.  Itinteang T, Marsh R, Davis PF, Tan ST. Angiotensin II causes cellular proliferation in infantile haemangioma via angiotensin II
                   receptor 2 activation. J Clin Pathol 2015;68:346-50.
               33.  Koh SL, Ager EI, Costa PLN, Malcontenti-Wilson C, Muralidharan V, et al. Blockade of the renin-angiotensin system inhibits growth
                   of colorectal cancer liver metastases in the regenerating liver. Clin Exp Metastas 2014;31:395-405.
               34.  Januel E, Ursu R, Alkhafaji A, Marantidou A, Doridam J, et al. Impact of renin-angiotensin system blockade on clinical outcome in
                   glioblastoma. Eur J Neurol 2015;22: 1304-9.
   836   837   838   839   840   841   842   843   844   845   846